Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Non-Hodgkin Lymphoma Clinical Trials

17 recruiting trials for Non-Hodgkin Lymphoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
17
Total Trials
17
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT03050268

Familial Investigations of Childhood Cancer Predisposition

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many...

Sponsor: St. Jude Children's Research HospitalEnrolling: 15001 location
RECRUITINGNCT07259304

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young...

Sponsor: University of Southern CaliforniaEnrolling: 2501 location
RECRUITINGEarly Phase 1NCT06393335

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory...

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies

Sponsor: The Children's Hospital of Zhejiang University School of MedicineEnrolling: 361 location
RECRUITINGPhase 2NCT05283720

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the...

Sponsor: GenmabEnrolling: 49620 locations
RECRUITINGPhase 1 / Phase 2NCT06768905

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion in patients with...

Sponsor: University of Texas Southwestern Medical CenterEnrolling: 301 location
RECRUITINGPhase 1NCT06447376

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after...

Sponsor: Taylor BrooksEnrolling: 201 location
RECRUITINGNCT06002828

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both...

Sponsor: ECOG-ACRIN Cancer Research GroupEnrolling: 200020 locations
RECRUITINGNCT06004011

AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)

Adolescents and young adults living with HIV experience higher premature mortality from cancer than their uninfected peers. In Zambia, because of multilevel barriers,...

Sponsor: ImplenomicsEnrolling: 41001 location
RECRUITINGPhase 1NCT06026319

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated...

Sponsor: Marcela V. Maus, M.D.,Ph.D.Enrolling: 241 location
RECRUITINGPhase 2NCT06563596

Epco, Zanu, Ritux for R/R FL or MZL

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory...

Sponsor: Reid Merryman, MDEnrolling: 453 locations
RECRUITINGPhase 1NCT05653271

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell...

Sponsor: Acepodia Biotech, Inc.Enrolling: 4213 locations
RECRUITINGPhase 2NCT05346809

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell...

Sponsor: Divaya BhutaniEnrolling: 392 locations
RECRUITINGNCT05839210

Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

The purpose of this study is to investigate if a mediterranean diet and exercise program for Lymphoma patients during chemotherapy can improve treatment completion and reduce...

Sponsor: University of MiamiEnrolling: 1401 location
RECRUITINGPhase 2NCT07188090

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation....

Sponsor: Thomas Jefferson UniversityEnrolling: 1001 location
RECRUITINGPhase 3NCT05645107

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to...

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major...

Sponsor: Grifols Therapeutics LLCEnrolling: 38620 locations
RECRUITINGNCT01962636

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases,...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 2001 location
RECRUITINGPhase 2NCT03852407

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG...

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement...

Sponsor: University of LiegeEnrolling: 11410 locations